Novartis continues its pivot toward specialized medicines by acquiring Endocyte.
News & Analysis: Endocyte
Here's what needs to happen to see more gains from these high-flying drugmakers.
A quicker pathway to approval had shares up, then the company decided to use the opportunity to raise additional capital.
Find out what's pushing shares of these biotechs through the roof.
Find out how six drugmakers tripled their shareholders' money in six short months.
The meeting hasn't even started, and stocks are already moving.
Investors are excited about updated data from a phase 2 trial of its prostate cancer drug.
These highfliers could could climb higher. Here's what needs to happen.
Find out how these strong performers surged in less than nine months -- and what lies ahead for them.
See which stocks climbed on another tumultuous market day.